Search
-
Healthcare vs Evolution: Can GLP-1s Rewrite Our Evolutionary Story?
Our evolutionary tale began 6 million years ago, when humans were programmed to hoard calories in a world of scarcity. Today, that ancient wiring has become our greatest health risk.
-
Bringing Healthcare Segmentations to Life: The Dawn of the GenAI-Powered Persona
Enter the age of generative AI, ushering in a new era of possibility with the advent of the persona bot – a tool with the potential to revolutionise how pharmaceutical companies activate and leverage segmentation data.
-
Synthetic Data: From Hype to Reality - A Guide to Responsible Adoption
Synthetic data, powered by AI, is poised to transform the market research industry. The question isn’t if, but when and how. Recognizing the potential, but also the possible pitfalls, of the issue, our clients asked us to provide Ipsos’ trusted perspective on the topic.
-
A Dose of Digital: Can Pharma Make DTx a Healthy Business?
Digital therapeutics (DTx) are emerging as a potential game-changer in healthcare, offering evidence-based digital interventions to help prevent, manage, or treat specific conditions.
-
ESG in life sciences as a hidden driver for brand success
There is a growing belief among the public that private corporations should also take responsibility for environmental, social, and governance (ESG) issues; these factors are no longer solely the responsibility of the public and governments. While certain business sectors are perceived as having a heightened obligation to diminish their environmental footprint (particularly energy companies, automobile manufacturers, airlines, and public transport providers), no industry can evade the necessity to act responsibly.
-
Crisis Management
With such high expectations of businesses, there is much more room for perceived missteps and loud criticisms from various stakeholders.
-
Why is cryptocurrency still confusing?
Social data reveals what’s holding consumers back from embracing crypto